Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab with or without oral decitabine/cedazuridine in anti-PD-1/PD-L1-resistant melanoma and NSCLC
2024-518891-29-00Phase 2Authorised
- Sponsor
- Fondazione NIBIT
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in melanoma and non-small cell lung cancer (NSCLC) comparing ASTX727 + nivolumab + ipilimumab with nivolumab + ipilimumab (2 arms). Primary endpoint: Tumor assessment by iRECIST. Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-518891-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518891-29-00.